Locator: 46567ARCHIVES.

Wow, the content just doesn't quit. 

Every night my wife and I watch an old series from 6:00 p.m. to 7:00 p.m. or thereabouts. Some years ago it was Perry Mason, then Columbo, then Monk (our all-time favorite -- we went through the series twice), then a lot of Psych. But we're up against a wall. She still has many favorite shows but none that we both like. But tonight, of all things, I ran into a "new" series. I just watched the first episode. I think my wife will love it. We'll watch tomorrow night. White Collar.

The point? There is no point. Except that the content available these days is incredible.

**********************
CRISPR

Link here.

Transfuion-dependent beta thalassemia.

The U.S. health regulator has approved Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 12 years and older, Vertex said on Tuesday.

The decision earns the therapy, branded as Casgevy, the second U.S. approval after it was greenlighted in December for sickle cell disease, another inherited blood disorder.

The approval by the Food and Drug Administration comes more than two months ahead of its expected action date of March 30.

Casgevy, which requires administration through authorized treatment centers with experience in stem cell transplantation, would be made available early this year at a list price of $2.2 million in the United States for both the approved indications, Vertex said in an email response.

*************************